CARD9 mediated MAPK/NF-κB signal pathway participates in the pathophysiological process of septic hepatitis: The role of tiliroside

The purpose of the present study was to search for biomarker and effective treatment measures for septic hepatitis. Lipopolysaccharide (LPS) was used to establish septic hepatitis (SH) model in vivo and in vitro. Proteomics, immunoprecipitation, molecular docking techniques, and CARD9 knockout (KO) mice and silence Chang liver Cell (CLC) were used to search for biomarker and possible treatment targets and treatment measures for SH. 46 differentially expressed proteins were found in the liver tissues of sepsis mice, among which CARD9 changed most. CARD9 KO and silence significantly relieved sepsis induced SH in vivo and in vitro. Tiliroside (TIS), an effective component of Buddleja officinalis Maxim, significantly improved SH by regulating CARD9 mediated MAPK/NF-kappa B signal pathway. In conclusion, CARD9 may be the important molecular targets for SH. TIS could protect SH via CARD9 mediated MAPK/NF-kappa B signal pathway. The findings provide a new treatment target for SH and a potential treatment measure.

Automated summary

This study identified biomarkers for septic hepatitis and proposed CARD9 and TIS as potential treatment targets. The results suggested that CARD9 may serve as an important molecular target for septic hepatitis, while TIS can protect against septic hepatitis by regulating the CARD9-mediated signaling pathway.